Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

Nat Rev Cancer. 2002 Nov;2(11):826-35. doi: 10.1038/nrc925.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Blood Vessels / drug effects
  • Blood Vessels / pathology*
  • Bone Marrow Cells / pathology
  • Cell Differentiation
  • Cell Lineage
  • Cell Movement
  • Endothelial Growth Factors / physiology
  • Endothelium, Vascular / pathology
  • Forecasting
  • Hematopoietic Stem Cells / drug effects*
  • Humans
  • Intercellular Signaling Peptides and Proteins / physiology
  • Lymphokines / physiology
  • Matrix Metalloproteinase 9 / physiology
  • Mice
  • Mice, Knockout
  • Neoplasm Proteins / physiology
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy
  • Neoplasms, Experimental / blood supply
  • Neoplasms, Experimental / drug therapy
  • Neovascularization, Pathologic / drug therapy*
  • Stem Cells / drug effects*
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-1 / physiology
  • Vascular Endothelial Growth Factor Receptor-2 / physiology
  • Vascular Endothelial Growth Factors

Substances

  • Angiogenesis Inhibitors
  • Endothelial Growth Factors
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • Neoplasm Proteins
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor Receptor-2
  • Matrix Metalloproteinase 9